title: Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.
abstract: The goals of therapy in inflammatory bowel disease (IBD) are the induction and maintenance of clinical and biological remission. Mucosal healing is desirable to prevent complications and reduce the need for surgery, hospitalizations, and steroid exposure. Therapeutic monoclonal antibodies (biologic agents) have revolutionized the treatment of IBD. The initial magnitude of the clinical/biologic response to these agents has been associated with a number of underlying phenotypic features in the recipient. In addition, the durability of the initial response often declines over time. This can occur due to low drug serum drug levels, anti-drug antibodies, and a shift to alternative inflammatory pathways. This review discusses strategies that may optimize the initial response to biologics and sustain this to improve patient outcomes.
authors.affiliation: Beth Israel Deaconess Medical Center & Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.
authors.forename: Aoibhlinn
authors.initials: A
authors.lastname: O'Toole
authors.forename: Alan C
authors.initials: AC
authors.lastname: Moss
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D016903:Drug Monitoring / Q000379:methods; D057915:Drug Substitution; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use
chemical_list: D001685:Biological Factors; D000069285:Infliximab; D000068879:Adalimumab